Itziar García-Ruiz

Itziar García-Ruiz

Auto-generated profile, based on publicly available information

Itziar García-Ruiz

Obstetrics Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2020 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
MMManel Mendoza
Manel Mendoza
IGItziar Garcia‐Ruiz
Itziar Garcia‐Ruiz
NMNerea Maiz
Nerea Maiz
CRCarlota Rodó
Carlota Rodó
PGPablo Garcia-Manau
Pablo Garcia-Manau
ASAnna Suy
Anna Suy

14 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CMCristina Saura Manich
Cristina Saura Manich
COCarolina Ortiz
Carolina Ortiz
JMJudit Matito
Judit Matito
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
ASAnna Suñol
Anna Suñol
MSMiriam Sansó
Miriam Sansó
Breast cancer occurring during pregnancy (PrBC) and postpartum (PPBC) is usually diagnosed at more advanced stages compared with other breast cancer, worsening its prognosis. PPBC is particularly aggressive, with increased metastatic risk and mortality. Thus, effective screening methods to detect early PrBC and PPBC are needed. We report for the first time that cell-free tumor DNA (ctDNA) is present in breast milk (BM) collected from patients with breast cancer. Analysis of ctDNA from BM detects tumor variants in 87% of the cases by droplet digital PCR, while variants remain undetected in 92% of matched plasma samples. Retrospective next-generation sequencing analysis in BM ctDNA recapitulates tumor variants, with an overall clinical sensitivity of 71.4% and specificity of 100%. In two cases, ctDNA was detectable in BM collected 18 and 6 months prior to standard diagnosis. Our results open up the potential use of BM as a new source for liquid biopsy for PPBC detection. Significance: For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image. See related commentary by Cunningham and Turner, p. 2125. This article is featured in Selected Articles from This Issue, p. 2109

3 May 2022 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
BSBerta Serrano
Berta Serrano
MMManel Mendoza
Manel Mendoza
PGPaula Garcia‐Aguilar
Paula Garcia‐Aguilar
EBErika Bonacina
Erika Bonacina
IGItziar Garcia‐Ruiz
Itziar Garcia‐Ruiz
ECElena Carreras
Elena Carreras
Introduction: The association between preeclampsia and coronavirus disease 2019 (COVID‐19) is under study. Previous publications have hypothesized the existence of shared risk factors for both conditions or a deficient trophoblastic invasion as possible explanations for this association. The primary aim of this study was to examine baseline risk factors measured in the first‐trimester combined screening for preeclampsia in pregnant women with COVID‐19 compared with the general population. A secondary aim of this study was to compare risk factors among patients with mild and severe COVID‐19.Material and Methods: This was an observational retrospective study conducted at Vall d'Hebron Hospital Campus (Catalonia, Spain). Study patients were 231 pregnant women undergoing the first‐trimester screening for preeclampsia and positive for severe acute respiratory syndrome coronavirus 2 between February 2020 and September 2021. The reference cohort were 13 033 women of the general population from six centers across Catalonia from May 2019 to June 2021. Based on the need for hospitalization, patients were classified in two groups: mild and severe COVID‐19. First‐trimester screening for preeclampsia included maternal history, mean arterial blood pressure, mean uterine artery pulsatility index (UtAPI), placental growth factor (PlGF), and pregnancy‐associated plasma protein‐A (PAPP‐A).Results: The proportion of cases at high risk for preeclampsia was significantly higher among the COVID‐19 group compared with the general population (19.0% and 13.2%, respectively; p = 0.012). When analyzing risk factors for preeclampsia individually, women with COVID‐19 had higher median body mass index (25.2 vs 24.5, p = 0.041), higher UtAPI multiple of the median (MoM) (1.08 vs 1.00, p < 0.001), higher incidence of chronic hypertension (2.8% vs 0.9%, p = 0.015), and there were fewer smokers (5.7% vs 11.6%, p = 0.007). The MoMs of PlGF and PAPP‐A did not differ significantly between both groups (0.96 vs 0.97, p = 0.760 and 1.00 vs 1.01, p = 0.432; respectively).Conclusions: In patients with COVID‐19, there was a higher proportion of women at high risk for preeclampsia at the first‐trimester screening than in the general population, mainly because of maternal risk factors, rather than placental signs of a deficient trophoblastic invasion.

12 December 2025
Verified
Other
Open access
CMCristina Saura Manich
Cristina Saura Manich
COCarolina Ortiz
Carolina Ortiz
JMJudit Matito
Judit Matito
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
ASAnna Suñol
Anna Suñol
MSMiriam Sansó
Miriam Sansó
Complete information of the Case cohort, with clinical features and results from the somatic mutation analysis

12 December 2025
Verified
Other
Open access
CMCristina Saura Manich
Cristina Saura Manich
COCarolina Ortiz
Carolina Ortiz
JMJudit Matito
Judit Matito
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
ASAnna Suñol
Anna Suñol
MSMiriam Sansó
Miriam Sansó
Sensitivity of the BM ctDNA detection assays.

12 December 2025
Verified
Other
Open access
CMCristina Saura Manich
Cristina Saura Manich
COCarolina Ortiz
Carolina Ortiz
JMJudit Matito
Judit Matito
Enrique Javier ArenasEnrique Javier Arenas
Enrique Javier Arenas
ASAnna Suñol
Anna Suñol
MSMiriam Sansó
Miriam Sansó